Finasteride concentrations and prostate cancer risk: results from the prostate cancer prevention trial.

Publication Type:

Journal Article


PloS one, Volume 10, Issue 5, p.e0126672 (2015)


In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the risk of prostate cancer by 25%, even though high-grade prostate cancer was more common in the finasteride group. However, it remains to be determined whether finasteride concentrations may affect prostate cancer risk. In this study, we examined the association between serum finasteride concentrations and the risk of prostate cancer in the treatment arm of the PCPT and determined factors involved in modifying drug concentrations.